Companies: 10,795·Total market cap: $144.5T
Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc.

CYTNASDAQHealthcare
$3.02
$-0.07(-2.27%)
Market Cap$108714262
P/E Ratio—
52W High$3.19
52W Low$1.65
ForecastMarket CapPE Ratio

Cyteir Therapeutics, Inc.（CYT）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

cyt · 股价预测 · 5 位分析师（近3月）· FMP · 更新于 2024年6月28日

分析师评级与共识

基于过去 3 个月内 5 位华尔街分析师

SellBuy

Buy

5 位分析师

共识

评级分布

Strong Buy
0
Buy
2
Hold
1
Sell
2
Strong Sell
0
合计: 5 · 买入占比: 40.0%

12 个月目标价

High

$2.00

Consensus

$2.00

-33.6% upside

Low

$2.00

Median: $2 · Last Close: $3.01

Cyteir Therapeutics, Inc.（CYT）的分析师共识为 Buy，基于过去 3 个月内 5 位华尔街分析师的评级。CYT 的 12 个月平均目标价为 $2.00，相对当前价 $3.01 代表 -33.6% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

⚠️ 短期模型暂不可用——近期成交量过低，信号不可靠。

长期股价预测

⚠️ 长期模型暂不可用——成交量过低，信号不可靠。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

21%8%71%
3Buy
1Neutral
10Sell
RSI (14)100.0Overbought
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · CYT · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$3.01NEUTRAL
MA 10$3.01BUY
MA 20$3.01SELL
MA 50$3.06SELL
MA 100$3.07SELL
MA 200$2.94BUY
Current $CYT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$3.01SELL
EMA 10$3.01SELL
EMA 20$3.02SELL
EMA 50$3.04SELL
EMA 100$3.02SELL
EMA 200$2.94BUY
Current $CYT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
B of A Securities2024-01-05
Downgrade ↓
Neutral→Underperform
Wedbush2023-05-12
Maintains
Outperform→Outperform
Wedbush2023-05-11
Maintains
Outperform→Outperform
Morgan Stanley2023-02-03
Downgrade ↓
Equal Weight→Underweight
Morgan Stanley2023-02-02
Downgrade ↓
Equal Weight→Underweight
B of A Securities2023-01-30
Downgrade ↓
Buy→Neutral
B of A Securities2023-01-29
Downgrade ↓
Buy→Neutral
JP Morgan2023-01-20
Downgrade ↓
Overweight→Neutral
JP Morgan2023-01-19
Downgrade ↓
Overweight→Neutral
Morgan Stanley2022-09-09
Downgrade ↓
Overweight→Equal Weight

Wall Street analysts have recently issued updated ratings on Cyteir Therapeutics, Inc. (CYT) stock. Of the recent 18 rating actions, 0 were upgrades and 9 were downgrades. 5 analysts currently cover CYT.

分析师推荐趋势

Buy ratings2 → 0↓ 2
Hold ratings0 → 0
Sell ratings0 → 1↑ +1

CYT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$0M

Revenue Next Year

$0M

EPS This Year

$-1.15

EPS Next Year

$-1.36

↑ 18.4% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CYT EPS of $-1.15 for the current fiscal year, based on estimates from 1 analysts. The CYT revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

CYT 股价预测由两类独立数据源支撑：来自 5 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CYT 的共识目标价为 $2.00（-33.6% 上行空间），分析师共识为 Buy。

Cyteir Therapeutics, Inc. 在 NASDAQ 上市，代码 CYT。CYT 在 2027 年的整体展望偏积极，在覆盖分析师中约 40% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

CYT 预测 · 8 个问题

根据 5 位华尔街分析师，CYT 的 12 个月平均目标价为 $2.00，最高 $2.00、最低 $2.00。若有图表，中位目标价可在上方查看。相对当前价 $3.01，隐含约 -33.6% 的上行空间。

CYT 目标价CYT 分析师目标价CYT 12个月目标价目标价 CYT

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.